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Abstract
Background Risk stratification in patients with atrial fibrilla-
tion (AF) is critically important because this group is at high
risk of mortality and morbidity. One of the comorbidities po-
tentially affecting thromboembolic and total cardiovascular
risk is obstructive sleep apnea (OSA). The aim of this study
was to determine whether or not patients with atrial fibrillation
and concomitant obstructive sleep apnea have a higher pre-
dicted cardiovascular risk than those without sleep-disordered
breathing.
Methods The study was designed to be a cross-sectional ob-
servational study. Consecutive patients with primary diagno-
sis of AF who qualified for first-ever catheter ablation be-
tween 2011 and 2013 were enrolled. All patients had an over-
night polysomnography performed for the diagnosis of OSA
and calculation of a 2MACE score—a cardiovascular risk
assessment score for AF.
Results Westudied211AFpatients (meanage57.1±10.2years,
62.6% males). OSA with apnea-hypopnea index (AHI) ≥15/h
was found in 48 patients (22.7%). Cardiovascular disease and
risk factors were as follows: 8 (3.8%) patients had congestive
heart failure, 27 (12.8%) diabetes, 16 (7.6%) history of stroke or
thromboembolic disease, 194 (91.9%) arterial hypertension, 24
(11.4%) vascular disease, and 31 (14.7%) were current
smokers. A significantly higher percentage of patients with
OSA was at high risk of cardiovascular disease (29.2 vs.
8.1%; p < 0.0001). The trend remained significant in different
categories of obstructive sleep apnea when categorized by AHI
into non-OSA, and mild, moderate, and severe OSA. Similarly,
the mean 2MACE score was statistically significantly higher in
OSA than non-OSA patients (2.1 ± 1.1 vs. 1.4 ± 1.0;
p < 0.0001).
Conclusion OSA prevalence is increased in AF patients and is
associated with an increase 2MACE score—an indicator of
major cardiovascular events. There is a linear relationship be-
tween severity of OSA and increasing 2MACE scores, indi-
cating increasing cardiovascular risk related to OSA severity.





CABG Coronary artery bypass grafting
CI Confidence interval
CVD Cardiovascular diseases
MACE Major adverse coronary events
MI Myocardial infarction
OSA Obstructive sleep apnea
Introduction
Patients with atrial fibrillation (AF) are at increased risk of
cardiovascular disease (CVD) and death [1]. Therefore, exten-
sive measures are applied in order to stratify their risk (i.e., of
bleeding and thromboembolism). To effectively manage the
risk in patients with AF, it is useful to use assessment scales
such as CHA2DS2-VASc, HAS-BLED, or the 2MACE score
[2, 3] which was recently developed for assessment of cardio-
vascular risk in AF patients.
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Obstructive sleep apnea (OSA) is a disease highly preva-
lent in patients with AF. It is also a strong risk factor for CVD
in the general population. Unfortunately, OSA is not routinely
included in any of the risk assessment schemes for AF.
Currently, there are no data on how the presence of OSA
affects risk assessment and if OSA impairs the validity of risk
assessment scores.
The aim of this study was to determine whether or not
patients with AF and concomitant OSA have a higher predict-
ed cardiovascular risk than those without OSA, according to
the 2MACE score.
Methods
All study design details were described previously [4]. The
study was designed to be a cross-sectional observational
study. Consecutive patients with primary diagnosis of AF
who qualified for first-ever catheter ablation between 2011
and 2013 were enrolled. Inclusion criteria were age ≥18 years,
confirmed diagnosis of nonvalvular AF, and prequalification
for invasive treatment of arrhythmia (catheter ablation or car-
dioversion). Patients with valvular AF, myocardial infarction,
or decompensation of heart failure within 6 months prior to
study entry, estimated life expectancy of ≤6 months, acute
and/or chronic pulmonary diseases such as obstructive pulmo-
nary disease or active tuberculosis, neuromuscular disease,
hemochromatosis, severe neurologic or psychiatric disorders,
or patients who did not give an informed consent were exclud-
ed from the study. The study was designed and conducted
with the accordance of the Declaration of Helsinki and was
approved by the University Ethics Committee.
Diagnosis of atrial fibrillation
Diagnosis of AF was made in accordance with the European
Society of Cardiology Guidelines, requiring at least one ar-
rhythmia episode recorded in a 24-h ECG Holter monitor
during the 6 months before study enrollment. Paroxysmal
AF was defined as self-terminating (up to 7 days), while per-
sistent AF was diagnosed when an arrhythmia episode lasted
longer than 7 days or required termination by cardioversion.
Cardiovascular risk assessment
All definitions of the primary endpoints and diagnosis of con-
comitant disease were made according to the 2MACE valida-
tion study [3]. In the validation study, MACE included fatal/
nonfatal myocardial infarction (MI), cardiac revascularization
(stent or coronary artery bypass surgery/CABG), and cardio-
vascular death. The diagnosis of MI was made according to
the definition proposed by the Joint ESC/ACCF/AHA/WHF
Task Force. If a patient died within 4 weeks of MI, this event
was recorded as fatal MI. Death was classified as vascular
unless an unequivocal noncardiovascular cause of death was
identified. Cardiovascular death included sudden death, pro-
gressive congestive heart failure, or procedure-related death
(surgical or percutaneous revascularization).
Cardiovascular risk factors were also defined as in the val-
idation study [3]: arterial hypertension—repeatedly elevated
blood pressure (>140/90 mmHg) or taking antihypertensive
drugs; diabetes—a random plasma glucose >200 mg/dl
(11.1 mmol/l), or fasting plasma glucose >126 mg/dl
(7.0 mmol/l), or 2-h plasma glucose >200 mg/dl (11.1 mmol/
l) during an OGTTor taking antidiabetic drugs; heart failure—
the presence of signs and symptoms typical of heart failure or
reduced ejection fraction (<40%). The metabolic syndrome
was defined according to modified ATP-III criteria.
The 2MACE score was calculated as follows: 2 points each
were assigned for metabolic syndrome and age ≥75 years, and
1 point each for myocardial infarction/revascularization, con-
gestive heart failure (ejection fraction <40%) and thromboem-
bolism (stroke/transient ischemic attack) for a range of 0 to 7
points (Table 1). Patients with 2MACE score ≥3 points were
considered at high cardiovascular risk.
Sleep study evaluation
All patients included in the study were studied with overnight
polysomnography irrespective of their daytime and nighttime
symptoms. Polysomnography was performed using devices
recording >4 channels including channels to detect respiratory
movements or respiratory effort, airflow, heart rate, ECG, and
oxygen saturation (Embletta Gold; Flaga, Reykjavik, Iceland).
All sleep study results were scored manually according to the
current guidelines. Apnea was defined as a reduction of air-
flow of ≥90% of pre-event baseline lasting ≥10 s. Hypopnea
was defined as a ≥30% drop in maximal airflow lasting ≥10 s,
associated with ≥3% oxygen desaturation from pre-event
baseline [5]. OSA was diagnosed based on the apnea-
hypopnea index (AHI, the number of apneas and hypopneas
per hour) and categorized into three severity classes: mild
OSA–AHI ≥5 and <15 per hour, moderate OSA–AHI ≥15
and <30 per hour, and severe OSA–AHI ≥30 per hour.
Statistical analysis
Data were tested for normality using the Kolmogorov–
Smirnov test. Continuous data are presented as mean and
95% confidence intervals (CIs), with statistical comparisons
performed with the Mann–Whitney test or Student’s t test. For
categorical variables, comparison was made using either the
chi-squared or Fisher exact tests. A Pearson correlation was
used to determine the correlation coefficient between sleep
disorder severity and 2MACE score. A one-way analysis of
covariance (ANCOVA) was used to determine associations
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between body mass index and OSAwhile controlling for rel-
evant cofactors. A p value of less than 0.05 was considered
statistically significant. Statistical analyses were performed
using SPSS (SPSS version 21, Inc., Chicago, IL).
Results
We enrolled 211 patients withAF (mean age 57.1 ± 10.2 years,
62.6% males). The majority of patients (148, 70%) presented
with paroxysmal AF, while the remaining patients had
sustained AF. Prevalence of cardiovascular disease and risk
factors was as follows: 8 patients (3.8%) had congestive heart
failure, 27 (12.8%) diabetes, 16 (7.6%) history of stroke or
thromboembolic disease, 194 (91.9%) arterial hypertension,
24 (11.4%) vascular disease, and 31 (14.7%) were current
smokers or had history of smoking in two previous years.
Mild OSAwas found in 39 (18.5%) patients, moderate in 30
(14.2%), and severe in 18 (8.5%) patients (Table 2).
We observed that the presence of OSA significantly influ-
enced the prevalence of some cardiovascular diseases and risk
factors, including arterial hypertension. Detailed characteris-
tics of patients according to the presence of sleep disordered
breathing severity are presented in Table 3. There were no
differences regarding age, but other parameters, including
sex and body mass index, were different between the groups
with and without OSA.
A significantly higher percentage of patients with OSAwas
at high risk for cardiovascular disease (29.2 vs. 8.1%;
p < 0.0001). The trend remained significant in different catego-
ries of mild, moderate, and severe OSA (Fig. 1). Similar obser-
vations were made for mean 2MACE scores which were statis-
tically significantly higher in patients with OSA than patients
without OSA (2.1 ± 1.1 vs. 1.4 ± 1.0; p < 0.0001). The results
remained significant according to severity of disease (Fig. 2).
There was a weak positive correlation between AHI and
2 MACE scores (correlation coefficient = 0.369, p < 0.0001).
In order to test the association between OSA severity,
2MACE scores, and BMI, statistical analysis using
ANCOVAwas performed. There were 33 patients with normal
body weight (BMI 18–24.99 kg/m2), 90 patients who were
overweight (BMI 25–29.99 kg/m2), and 88 who patients were
obese (BMI >30 kg/m2) (Fig. 3). There was no statistically
significant difference in the mean BMI (F = 0.31, p = 0.575)
or age (F = 0.045, p = 0.831) between patients with OSA and
patients with no OSA. No interaction was shown between
OSA and age (F = 0.014, p = 0.907).
Discussion
The present study showed that in patients with AF, the pres-
ence of OSA is associated with an increased 2MACE score.
This translates to a higher risk of cardiovascular disease seen
in patients with concomitant AF and OSA. The current study
also showed that cardiovascular risk assessed with the
2MACE score is correlated with higher AHI. Therefore, se-
verity of OSA is important and should be considered in the
CVD risk stratification of AF patients.
Current epidemiological studies indicate that OSA occurs
in about 24% of men and 9% of women in the general popu-
lation aged between 30 and 60 years [6]. Occurrence of OSA
combined with signs of daytime sleepiness in approximately
4% of men and 2% of women [6]. Nevertheless, a significant
Table 2 Baseline characteristics of the study population
Parameter Value
Age (years) 57.1 ± 10.2
BMI (kg/m2) 29.7 ± 4.8
AHI (per hour) 3.6 (1.2–13.1)
Oxygen desaturation index 4.1 ± 3.6
Mean oxygen saturation 93.4 ± 2.8
Minimal recorded saturation 91.3 ± 4.7
Female sex 79 (37.4%)
Congestive heart failure 8 (3.8%)
Diabetes mellitus 27 (12.8%)
Stroke/thromboembolism 16 (7.6%)
Arterial hypertension 194 (91.9%)
Vascular disease 24 (11.4%)
Smoking 31 (14.7%)
Metabolic syndrome 150 (71.1%)
Paroxysmal AF 148 (70.1%)
Mean 2MACE 1.7 ± 1.1
Patients with 2MACE ≥3 36 (17.1%)
Values are presented as mean ± standard deviation (SD), median (inter-
quartile range), or n (%)
AF atrial fibrillation, AHI apnea-hypopnea index, BMI body mass index
Table 1 Definition of the
2MACE score Acronym Definition Points
2M History of myocardial infarction/cardiac revascularization 1
Metabolic syndrome 2
A Age (>75 years) 2
C Congestive heart failure (ejection fraction <40%) 1
E Thromboembolism 1
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proportion of cases remain undiagnosed. Data from the
American Academy of Sleep Medicine show that up to 80–
90% of patients with sleep disordered breathing are currently
underdiagnosed [7]. Even greater is the incidence of OSA is
seen in patients with atrial fibrillation. Previous studies have
shown that OSA is present in nearly 50% of patients with AF
[4]. In the present cohort, prevalence of moderate to severe
OSAwas 23%, which is greater than that in the general pop-
ulation. The particular importance of OSA in the present study
is its association with CVD.
Risk factors that cause OSA, including obesity, older age,
hormonal disorders (acromegaly, hypothyroidism), and ciga-
rette smoking also predispose to CVD. OSA results in inter-
mittent hypoxia, sympathetic activation, pulmonary hyperten-
sion, and variations in systemic blood pressure. This translates
to a higher incidence hypertension (often resistant to therapy),
coronary heart disease, myocardial infarction, heart failure,
arrhythmias, pulmonary hypertension, stroke, chronic kidney
disease, endothelial dysfunction, insulin resistance, metabolic
disorders, erectile dysfunction, increased blood clotting, stent
Table 3 Clinical characteristics
of patients according to the
severity of obstructive sleep
apnea (AHI)
Parameter Non-OSA/mild
OSA (n = 163)
Moderate to severe
OSA (n = 48)
p
Age (years) 56.5 ± 10.8 59.1 ± 7.5 0.26
BMI (kg/m2) 29.0 ± 4.6 32.0 ± 4.8 <0.0001
AHI (per hour) 2.5 (0.9–4.7) 23.6 (19.5–33.5) <0.0001
Oxygen desaturation index 3.1 ± 1.3 27.6 ± 3.5 <0.0001
Mean oxygen saturation 97.4 ± 1.8 91.3 ± 4.7 <0.0001
Minimal recorded saturation 93.1 ± 2.4 87.2 ± 3.6 <0.0001
Female sex 54 (33.1%) 25 (52.1%) 0.01
Congestive heart failure 1 (0.6%) 7 (14.6%) <0.0001
Diabetes mellitus 11 (6.7%) 16 (33.3%) <0.0001
Stroke/thromboembolism 10 (6.1%) 6 (12.5%) 0.13
Arterial hypertension 147 (90.2%) 47 (97.9%) 0.067
Vascular disease 13 (8.0%) 11 (22.9%) 0.007
Smoking 22 (13.5%) 9 (18.8%) 0.25
Metabolic syndrome (62.1%) (83.9%) <0.0001
Paroxysmal AF 121 (74.2%) 27 (56.3%) 0.02
Mean 2MACE 1.4 ± 1.0 2.1 ± 1.1 <0.0001
Patients with 2MACE ≥3 13 (8.1%) 14 (29.2%) <0.0001
Values are presented as mean ± standard deviation (SD), or median (interquartile range), or n (%)
AF atrial fibrillation, AHI apnea-hypopnea index, BMI body mass index
Fig. 1 Percentage of patients
with high cardiovascular risk in
the 2MACE score according to
the severity of obstructive sleep
apnea
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thrombosis, and chronic inflammation in patients with OSA
[8, 9].
It is recognized that second to nonadherence to therapy,
OSA is the leading cause of treatment failure in patients with
hypertension [10]. Oxidative stress, chronic inflammation,
and hypertension caused by OSA translate into damage to
the vascular endothelium and promote the development of
atherosclerotic plaques. One of the most important complica-
tions of OSA is atherosclerotic disease manifesting as stroke
or myocardial infarction [11, 12].
Another important issue is the impact of OSA on cardiac
arrhythmias. OSA is associated with increased incidence of
premature atrial beats, sinus bradycardia, sinus pauses, prema-
ture ventricular beats, and, what is crucial in the context of this
study—greatly increased incidence of AF [13]. Several stud-
ies have shown that nearly half of patients with AF meet the
criteria for diagnosis of at least mild OSA [14]. The occur-
rence of OSA in these patients results in worse outcomes. The
presence of OSA makes rhythm control strategies less effi-
cient and makes it harder to restore sinus rhythm either with
cardioversion or AF ablation [15, 16]. On the other hand, OSA
worsens outcomes, because patients with OSA and AF are at
increased risk of stroke and venous thromboembolism as
shown by higher CHADS2 and CHA2DS2-VASc scores in
association with higher AHI [17].
The newly developed 2MACE score is a useful tool by
which patients with AF may be screened for increased risk
of major cardiovascular events. However, the current study
Fig. 3 Relationship between
2MACE score and OSA index in
patients with different body mass
index
Fig. 2 Mean 2MACE score
according to the severity of
obstructive sleep apnea
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has several limitations. The present study is yet a preliminary
analysis, which needs to be validated in a larger cohort. For
proper validation, patients should be followed for a cardiovas-
cular event. Furthermore, interventional studies are needed to
clarify the impact of OSA treatment in high-risk patients to
reverse increased cardiovascular risk and related adverse out-
comes. Future investigations clarifying specific OSA and AF-
related pathways of cardiovascular risk may suggest targeted
preventive therapies to mitigate OSA-induced mortality and
morbidity in patients with AF.
Conclusions
OSA prevalence is increased in patients with AF and is asso-
ciated with an increased 2MACE score—a predictor of major
cardiovascular events. There is a linear relationship between
severity of OSA and increasing 2MACE score, indicating in-
creasing cardiovascular risk related to OSA severity.
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